SiriusPoint (SPNT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
9 Dec, 2025Executive summary
Completed major strategic reshaping, including CMIG share repurchase, loss portfolio transfer, de-risking of legacy MGA investments, and simplification of shareholder structure.
Achieved ninth consecutive quarter of underwriting profits, with FY24 Core combined ratio at 91.0% and underlying net income up 14% year-over-year to $304 million.
Book value per diluted common share (ex. AOCI) rose 9.8% to $14.64; underlying ROE reached 14.6%, at the top end of the 12%-15% target range.
Retired over $1 billion to investors and permanently retired 45.7 million shares, resulting in over 20% EPS accretion.
Maintained strong capital position with 15 consecutive quarters of favorable prior year development and robust balance sheet metrics.
Financial highlights
FY24 net income was $184 million; underlying net income up 14% to $304 million.
Core combined ratio for 2024 was 91%, a 2.4 point improvement year-over-year; Q4 core combined ratio was 90.2%, a 3.2 point improvement.
Net investment income for 2024 was $304 million, exceeding guidance.
Gross premiums written for continuing lines grew 10% for the year and 21% in Q4.
Book value per diluted common share increased 9.8% year-over-year to $14.64.
Outlook and guidance
Focus shifting to growth and performance enhancement in 2025, with continued disciplined underwriting and capital reallocation.
Expect to deliver a 12%-15% return on average common equity through the cycle.
FY25 net investment income guidance of $265m–$275m, reflecting reduced investment assets post-CMIG repurchase.
Headline premium in 2025 expected to grow at rates similar to 2024 continuing lines premium.
Effective tax rate to rise from 13% in 2024 to 19% in 2025 due to Bermuda tax changes.
Latest events from SiriusPoint
- Net income up 141%, premium up 16%, 16.2% ROE, and $100M buyback announced.SPNT
Q4 202519 Feb 2026 - Q2 net income $109.9M, book value up 7.2%, and share buyback authorization at $306.3M.SPNT
Q2 20242 Feb 2026 - Q3 2024 saw improved underwriting, strong investment income, and robust capital strength.SPNT
Q3 202417 Jan 2026 - 2025 AGM features director elections, say-on-pay, auditor approval, and highlights strong 2024 results.SPNT
Proxy Filing2 Dec 2025 - Q2 2025 saw strong premium growth, 17% ROE, and improved combined ratios despite catastrophe losses.SPNT
Q2 202523 Nov 2025 - Q1 2025: 12.9% ROE, strong premium growth, and upgraded ratings despite wildfire losses.SPNT
Q1 202518 Nov 2025 - Q3 2025 saw strong premium growth, improved underwriting, and higher ROE, with more value from MGA sales.SPNT
Q3 20252 Nov 2025